Immunocore (NASDAQ:IMCR) Rating Reiterated by HC Wainwright

HC Wainwright restated their buy rating on shares of Immunocore (NASDAQ:IMCR) in a research report released on Thursday, Benzinga reports. They currently have a $100.00 price objective on the stock.

IMCR has been the topic of a number of other reports. Mizuho decreased their target price on Immunocore from $90.00 to $88.00 and set a buy rating on the stock in a research report on Monday, May 13th. Leerink Partnrs reissued an outperform rating on shares of Immunocore in a research report on Monday, April 29th. Needham & Company LLC reissued a buy rating and set a $81.00 target price on shares of Immunocore in a research report on Friday, May 24th. SVB Leerink initiated coverage on Immunocore in a research report on Monday, April 29th. They set an outperform rating and a $74.00 target price on the stock. Finally, JPMorgan Chase & Co. lifted their price objective on Immunocore from $60.00 to $70.00 and gave the company an overweight rating in a report on Wednesday, March 20th. Two analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of Moderate Buy and an average target price of $81.85.

Immunocore Trading Up 4.9 %

Immunocore stock opened at $48.98 on Thursday. The company has a debt-to-equity ratio of 1.22, a quick ratio of 5.94 and a current ratio of 5.96. The business’s 50-day simple moving average is $56.93 and its 200-day simple moving average is $61.94. The firm has a market capitalization of $2.45 billion, a PE ratio of -40.15 and a beta of 0.92. Immunocore has a 52 week low of $41.01 and a 52 week high of $76.98.

Immunocore (NASDAQ:IMCR) last released its earnings results on Wednesday, May 8th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.12). Immunocore had a negative return on equity of 16.54% and a negative net margin of 22.60%. The firm had revenue of $70.30 million for the quarter, compared to analyst estimates of $70.72 million. During the same period last year, the business earned ($0.35) earnings per share. The firm’s quarterly revenue was up 27.6% compared to the same quarter last year. Equities research analysts forecast that Immunocore will post -1.88 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Exchange Traded Concepts LLC boosted its holdings in shares of Immunocore by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 2,656 shares of the company’s stock worth $181,000 after acquiring an additional 674 shares in the last quarter. Oppenheimer Asset Management Inc. raised its position in Immunocore by 26.6% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 7,491 shares of the company’s stock worth $389,000 after purchasing an additional 1,572 shares during the last quarter. Trexquant Investment LP raised its position in Immunocore by 6.5% in the 4th quarter. Trexquant Investment LP now owns 28,545 shares of the company’s stock worth $1,950,000 after purchasing an additional 1,746 shares during the last quarter. Allspring Global Investments Holdings LLC raised its position in Immunocore by 2.1% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 87,614 shares of the company’s stock worth $5,695,000 after purchasing an additional 1,830 shares during the last quarter. Finally, Great Point Partners LLC raised its position in Immunocore by 0.7% in the 4th quarter. Great Point Partners LLC now owns 293,000 shares of the company’s stock worth $20,018,000 after purchasing an additional 2,083 shares during the last quarter. 84.50% of the stock is owned by institutional investors and hedge funds.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.